{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-005733","form_type":"8-K","ticker":"TGTX","cik":"0001001316","company_name":"TG THERAPEUTICS, INC.","filed_at":"2026-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.367729+00:00","generated_at":"2026-05-15T23:21:04.482956+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"TG Therapeutics Q4 BRIUMVI US revenue $182.7M (+20% QoQ); 2026 revenue guidance raised to $875-900M","bullets":["Q4 total revenue $192.6M; full year 2025 $616.3M; BRIUMVI US net revenue $594.1M (+92% YoY).","Net income Q4 $23.0M; full year $447.2M including $339.8M non-recurring deferred tax asset benefit.","2026 guidance: total global revenue $875-900M; BRIUMVI US net $825-850M; Q1 2026 target $185-190M.","Completed $100M share repurchase (3.5M shares at avg $28.55); new $100M buyback authorized.","Pipeline milestones: ENHANCE IV data mid-2026; subcutaneous ublituximab data year-end 2026/1Q 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-005733","json":"https://secwatch.observer/filing/0001437749-26-005733.json","markdown":"https://secwatch.observer/filing/0001437749-26-005733.md","text":"https://secwatch.observer/filing/0001437749-26-005733.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001316/000143774926005733/0001437749-26-005733-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001316/000143774926005733/tgtx20251112_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:21:04.482956+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}